» Articles » PMID: 19627166

Progress on the Induction of Neutralizing Antibodies Against HIV Type 1 (HIV-1)

Overview
Journal BioDrugs
Date 2009 Jul 25
PMID 19627166
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Infection with HIV type 1 (HIV-1), the causative agent of AIDS, is one of the most catastrophic pandemics to affect human healthcare in the latter 20th century. The best hope of controlling this pandemic is the development of a successful prophylactic vaccine. However, to date, this goal has proven to be exceptionally elusive. The recent failure of an experimental vaccine in a phase IIb study, named the STEP trial, intended solely to elicit cell-mediated immune responses against HIV-1, has highlighted the need for a balanced immune response consisting of not only cellular immunity but also a broad and potent humoral antibody response that can prevent infection with HIV-1. This article reviews the efforts made up to this point to elicit such antibody responses, especially with regard to the use of a DNA prime-protein boost regimen, which has been proven to be a highly effective platform for the induction of neutralizing antibodies in both animal and early-phase human studies.

Citing Articles

Toll-Like Receptor and Cytokine Responses to Infection with Endogenous and Exogenous Koala Retrovirus, and Vaccination as a Control Strategy.

Kayesh M, Hashem M, Tsukiyama-Kohara K Curr Issues Mol Biol. 2021; 43(1):52-64.

PMID: 33946297 PMC: 8928999. DOI: 10.3390/cimb43010005.


Koala retrovirus epidemiology, transmission mode, pathogenesis, and host immune response in koalas (Phascolarctos cinereus): a review.

Kayesh M, Hashem M, Tsukiyama-Kohara K Arch Virol. 2020; 165(11):2409-2417.

PMID: 32770481 PMC: 7413838. DOI: 10.1007/s00705-020-04770-9.


HIV-1-Specific Antibody Response and Function after DNA Prime and Recombinant Adenovirus 5 Boost HIV Vaccine in HIV-Infected Subjects.

Gach J, Gorlani A, Dotsey E, Becerra J, Anderson C, Berzins B PLoS One. 2016; 11(8):e0160341.

PMID: 27500639 PMC: 4976892. DOI: 10.1371/journal.pone.0160341.


HIV-1 envelope glycoprotein resistance to monoclonal antibody 2G12 is subject-specific and context-dependent in macaques and humans.

Malherbe D, Sanders R, van Gils M, Park B, Gomes M, Schuitemaker H PLoS One. 2013; 8(9):e75277.

PMID: 24040404 PMC: 3767832. DOI: 10.1371/journal.pone.0075277.


Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially.

Pissani F, Malherbe D, Robins H, DeFilippis V, Park B, Sellhorn G Vaccine. 2012; 30(37):5519-26.

PMID: 22749601 PMC: 3447634. DOI: 10.1016/j.vaccine.2012.06.042.


References
1.
Wang S, Chou T, Sakhatskyy P, Huang S, Lawrence J, Cao H . Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system. J Virol. 2005; 79(3):1906-10. PMC: 544123. DOI: 10.1128/JVI.79.3.1906-1910.2005. View

2.
Boyer J, Wang B, Ugen K, Agadjanyan M, Javadian A, Frost P . In vivo protective anti-HIV immune responses in non-human primates through DNA immunization. J Med Primatol. 1996; 25(3):242-50. DOI: 10.1111/j.1600-0684.1996.tb00022.x. View

3.
Johnson W, Sanford H, Schwall L, Burton D, Parren P, Robinson J . Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities. J Virol. 2003; 77(18):9993-10003. PMC: 224602. DOI: 10.1128/jvi.77.18.9993-10003.2003. View

4.
Mascola J, Lewis M, Stiegler G, Harris D, Vancott T, Hayes D . Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol. 1999; 73(5):4009-18. PMC: 104180. DOI: 10.1128/JVI.73.5.4009-4018.1999. View

5.
Mascola J, Sambor A, Beaudry K, Santra S, Welcher B, Louder M . Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. J Virol. 2004; 79(2):771-9. PMC: 538538. DOI: 10.1128/JVI.79.2.771-779.2005. View